EMERGE
44 evidence topics · 16 sources
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Trial aim stated in the company announcement of initiation
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2026-06-29” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2028-12” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2031-09” (opens the source at this quote in a new tab)
“First Posted 2026-06-15” (opens the source at this quote in a new tab)
“Last Update Posted 2026-10-30” (opens the source at this quote in a new tab)
“Recruiting” (opens the source at this quote in a new tab)
“No Results Posted” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Study locations by country in the ClinicalTrials.gov record
| Country | Locations listed in the record |
|---|---|
| United States | “Pasadena, California, United States, 91106”; “Boca Raton, Florida, United States, 33432”; “Fayetteville, North Carolina, United States, 28304”; “Houston, Texas, United States, 77009” |
| Georgia | “Kutaisi, Georgia”; “Tbilisi, Georgia” |
| Ukraine | “Dnipro, Ukraine”; “Vinnytsia, Ukraine” |
Initiation announced by the company in June 2026
Expected timing of top-line results in the third-quarter 2026 filing
Expected timing of top-line results in the third-quarter 2026 results announcement
Planned update of top-line guidance in the November 2026 corporate deck
Member states and estimated dates in the EU trial record
Status and decision date by member state in the EU trial record
“Denmark Authorised, recruitment pending 28/09/2026” (opens the source at this quote in a new tab)
“France Authorised, recruitment pending 28/09/2026” (opens the source at this quote in a new tab)
“Latvia Authorised, recruitment pending 28/09/2026” (opens the source at this quote in a new tab)
“Portugal Authorised, recruitment pending 29/09/2026” (opens the source at this quote in a new tab)
“Bulgaria Authorised, recruitment pending 29/09/2026” (opens the source at this quote in a new tab)
“Germany Authorised, recruitment pending 30/09/2026” (opens the source at this quote in a new tab)
“Poland Authorised, recruitment pending 01/10/2026” (opens the source at this quote in a new tab)
“Italy Authorised, recruitment pending 01/10/2026” (opens the source at this quote in a new tab)
“Spain Authorised, recruitment pending 02/10/2026” (opens the source at this quote in a new tab)
“Austria Authorised, recruitment pending 05/10/2026” (opens the source at this quote in a new tab)
Study design
Official title in the ClinicalTrials.gov record
Study periods in the ClinicalTrials.gov detailed description
Allocation, model, and masking in the ClinicalTrials.gov record
Design summary in the November 2026 corporate deck
End-of-phase 2 meeting with FDA before the phase 3 trial
Eligibility criteria
Key inclusion criteria in the ClinicalTrials.gov record
“Weight range between 40-130 kg at Screening” (opens the source at this quote in a new tab)
“Acetylcholine receptor antibody (AChR Ab) positive” (opens the source at this quote in a new tab)
“MG-ADL scale score of 6 or more” (opens the source at this quote in a new tab)
“QMG scale score of 10 or more” (opens the source at this quote in a new tab)
“Ages Eligible for Study 18 Years to 80 Years” (opens the source at this quote in a new tab)
Key exclusion criteria in the ClinicalTrials.gov record
Inclusion criteria in the November 2026 corporate deck
Company rationale for the QMG screening criterion
Removal of antinuclear antibody screening after FDA written feedback
Treatment
Arms and interventions in the ClinicalTrials.gov record
Dose and route stated by the company
Rationale for the every-4-weeks regimen from the phase 2 open-label extension
Study outcomes
Rationale for using MG-ADL as the primary endpoint
Primary outcome measure in the ClinicalTrials.gov record
Secondary outcome measures in the ClinicalTrials.gov record
Primary and secondary endpoints stated by the company
MG-ADL scale described in the ClinicalTrials.gov record
Validity, reliability, and use of the MG-ADL as a primary endpoint
“Studies indicated that the MG‐ADL is a reliable and valid measure that has been used as an outcome in clinical trials and observational studies to measure MG symptoms and response to treatment. While most often used as a secondary endpoint in clinical trials, its use as a primary endpoint has increased in recent years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since trial completion and publication of results for the phase 3 trial of eculizumab, the use of the MG‐ADL as a primary endpoint in trials has become widespread. Of trials beginning in 2018 or later, 46.7% (n = 7) have used the MG‐ADL as a primary outcome compared to 10.0% (n = 2) of trials prior to 2018” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MG‐ADL is easy to administer, requires no additional training, is quick to complete (<10 min), and can be used in routine clinical” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimal clinically important difference: 2-point improvement in the validation study
“Correlation of the delta MG-ADL score and physician impression of change between the visits was strong (r = 0.70, P < 0.0001). A 2-point improvement in the MG-ADL best predicted clinical improvement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The MG-ADL correlates strongly with newer, validated MG outcome measures. A 2-point improvement in the MG-ADL indicates clinical improvement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Minimal clinically important difference: sensitivity and specificity of each threshold
“In this study, results from sensitivity and specificity analyses indicated that a 1‐point change in MG‐ADL was highly sensitive (96%) but did not have good specificity (71%), and a 3‐point change had good specificity (90%) but was not very sensitive (62%). A 2‐point change seemed to provide the best balance between sensitivity (77%) and specificity (82%); thus, this analysis revealed that a 2‐point improvement in MG‐ADL score best indicated clinical improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these 13 studies, 53.8% (n = 7) used a 2‐point improvement only, 30.8% (n = 4) used a 3‐point improvement only” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary endpoint in the pivotal trial of eculizumab
Primary endpoint in the pivotal trial of ravulizumab
Primary endpoint in the pivotal trial of zilucoplan
Primary endpoints in the pivotal trials of efgartigimod alfa
Primary endpoint in the pivotal trial of rozanolixizumab
Primary endpoint in the pivotal trial of nipocalimab
Company target for the MG-ADL treatment difference
Secondary endpoints: QMG and MGC scales described in the ClinicalTrials.gov record
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the ClinicalTrials.gov record
Planned participants per arm in the November 2026 corporate deck
| Arm | Planned participants |
|---|---|
| Claseprubart every 2 weeks | “300mg/2mL S.C. Q2W (N=65)” |
| Claseprubart every 4 weeks | “Claseprubart 300mg/2mL S.C. Q4W (N=65)” |
| Placebo | “Placebo (N=65)” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
EMERGE began on 2026-06-29 and has reported no efficacy or safety results; the company expects top-line results in the second half of 2028, and a company presentation lists updated EMERGE top-line guidance by the end of 2027. Enrollment is limited to approximately 195 adults aged 18 to 80 years who are acetylcholine receptor antibody positive, with an MG-ADL score of 6 or more and a QMG score of 10 or more, so participants with anti-MuSK, anti-LRP4, or seronegative generalized myasthenia gravis are not represented. The randomized, placebo-controlled period lasts 17 weeks, and longer-term data will come from an optional 104-week extended treatment period that includes an open-label extension.